4D Molecular Therapeutics (NASDAQ:FDMT) Shares Gap Up Following Analyst Upgrade

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT)’s stock price gapped up before the market opened on Thursday after Royal Bank Of Canada raised their price target on the stock from $32.00 to $35.00. The stock had previously closed at $8.56, but opened at $9.94. Royal Bank Of Canada currently has an outperform rating on the stock. 4D Molecular Therapeutics shares last traded at $8.8610, with a volume of 175,518 shares traded.

A number of other brokerages have also recently commented on FDMT. Weiss Ratings reissued a “sell (d-)” rating on shares of 4D Molecular Therapeutics in a research note on Wednesday, January 21st. Chardan Capital restated a “buy” rating and set a $26.00 target price on shares of 4D Molecular Therapeutics in a research report on Thursday. Wall Street Zen downgraded shares of 4D Molecular Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Finally, Barclays assumed coverage on shares of 4D Molecular Therapeutics in a research report on Wednesday, January 28th. They issued an “overweight” rating and a $33.00 price target on the stock. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $32.17.

Key Stories Impacting 4D Molecular Therapeutics

Here are the key news stories impacting 4D Molecular Therapeutics this week:

• Positive Sentiment: Q4 earnings and revenue materially beat expectations — reported EPS $0.43 vs. consensus ~($0.53) and revenue $85.09M vs. $30.86M expected, signaling stronger commercial performance than feared. Zacks: Q4 Results
• Positive Sentiment: Royal Bank of Canada raised its price target to $35 and assigned an “outperform” rating, providing a high upside thesis that can attract momentum buyers. Benzinga: RBC PT Raise
• Positive Sentiment: Chardan Capital reaffirmed a “buy” rating and set a $26 price target, reinforcing analyst support for the shares. Benzinga: Chardan Reaffirmation
• Positive Sentiment: Company press release outlining full‑year 2025 financial results, operational highlights and expected upcoming milestones provides an updated roadmap that may support continued upside if clinical/commercial milestones are achieved. GlobeNewswire: FY2025 Results & Milestones
• Neutral Sentiment: Short‑interest notices in mid‑March show anomalous/zero reported short shares (entries list 0 shares and NaN changes), which is ambiguous and unlikely to be driving meaningful short‑squeeze dynamics at this time.
• Negative Sentiment: Despite the beat, underlying metrics remain mixed: 4DMT reported a very large negative net margin and negative return on equity, and some analysts still expect negative full‑year EPS. These fundamentals keep valuation and profitability risks on the table. Press Release / Financials

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Dynamic Technology Lab Private Ltd acquired a new stake in shares of 4D Molecular Therapeutics during the 1st quarter worth about $39,000. Wexford Capital LP acquired a new position in shares of 4D Molecular Therapeutics in the third quarter valued at approximately $41,000. Quadrature Capital Ltd acquired a new position in shares of 4D Molecular Therapeutics in the second quarter valued at approximately $42,000. Farther Finance Advisors LLC lifted its stake in shares of 4D Molecular Therapeutics by 117.4% during the third quarter. Farther Finance Advisors LLC now owns 4,952 shares of the company’s stock valued at $43,000 after buying an additional 2,674 shares during the period. Finally, AQR Capital Management LLC purchased a new position in shares of 4D Molecular Therapeutics during the first quarter valued at approximately $46,000. Institutional investors and hedge funds own 99.27% of the company’s stock.

4D Molecular Therapeutics Price Performance

The stock’s 50-day moving average is $8.73 and its 200-day moving average is $9.08. The stock has a market cap of $513.03 million, a price-to-earnings ratio of -3.71 and a beta of 2.99.

4D Molecular Therapeutics (NASDAQ:FDMT) last released its earnings results on Wednesday, March 18th. The company reported $0.43 EPS for the quarter, topping the consensus estimate of ($0.53) by $0.96. The firm had revenue of $85.09 million during the quarter, compared to analysts’ expectations of $30.86 million. 4D Molecular Therapeutics had a negative net margin of 164.43% and a negative return on equity of 33.37%. Analysts predict that 4D Molecular Therapeutics, Inc. will post -2.84 EPS for the current fiscal year.

4D Molecular Therapeutics Company Profile

4D Molecular Therapeutics, founded in 2015 and headquartered in Emeryville, California, is a clinical-stage biotechnology company focused on the development of targeted gene therapies for rare diseases. The company employs its proprietary Gene Expression AAV (GEA) platform to engineer novel adeno-associated virus (AAV) capsids with enhanced tissue selectivity and transduction efficiency. This platform aims to improve the precision and durability of gene delivery compared to traditional AAV approaches.

4D’s pipeline includes both preclinical and clinical-stage programs across multiple therapeutic areas.